Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13444627 | 0.87 | LMNA (0.61) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL7101006 | 0.87 | MAPT (0.60) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL21659729 | 0.85 | POLB (0.68) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL5025348 | 0.84 | LMNA (0.70) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL11378981 | 0.84 | MAPT (0.57) | CA1CA2MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28694340 | 0.83 | POLB (0.66) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL9804183 | 0.83 | HPGD (0.63) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL3083718 | 0.83 | HPGD (0.63) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL751537 | 0.83 | PTGER4 (0.63) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL18158251 | 0.83 | POLB (0.74) | CA1CA2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
| CN-102985438-B | As the C-28 acid amides of the modified C-3 betulinic acid derivative of the ripe inhibitor of HIV | BRISTOL-MYERS SQUIBB CO. (US) | 2016-05-18 | — | — | CN | disclosed |
| EP-2576586-B1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8802661-B2 | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2576586-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-102985438-A | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2013-03-20 | — | — | CN | disclosed |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| WO-2011153319-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
| US-5352677-A | Antihyperlipidemic agents | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-10-04 | — | — | US | disclosed |
| EP-0407200-B1 | Cinnamamide derivatives | KANEGAFUCHI CHEMICAL IND (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5294643-A | Cinnamamide derivative | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5294624-A | Antiartheriosclerosis | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0407200-A1 | Cinnamamide derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4381401-A | Aminoethylation process | THE DOW CHEMICAL COMPANY (US) | 1983-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | ERG28, BET1, BRD3 | CA1 3214/4885CA2 2919/4885MAPT 2375/4885 |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | CA1 4448/4885CA2 3873/4885MAPT 2785/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | CA1 4448/4885CA2 3873/4885MAPT 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.